New Drugs 2015
• Edoxaban - Oral factor Xa inhibitor approved for DVT, pulmonary embolism and stroke prophylaxis in atrial fibrillation.
• Secukinumab - Anti IL 17 Ab approved for Psoriasis
• Isavuconazonium - Azole approved for invasive Aspergillosis and mucormycosis
• Avibactam - With Ceftazidime
• Panobinostat - Histone deacetylase inhibitor for multiple myeloma.
• Cobicistat - Its a CYP3A4 inhibitor approved for use with Atazanavir and Darunavir to increase their half life.
• Palbociclib - Cyclin dependent kinase inhibitor approved for ER/PR positive breast in post menopausal female in combination with aromatase inhibitor.
• Lenvatinib - VEGFR TK inhibitor approved for recurrent or metastatic thyroid ca refractory to I131.
• Nivolumab - Anti PD1 receptor Ab approved for metastatic squammous non small cell ca lung.
• Dinutuximab - Anti GD2 glycolipid Ab approved for neuroblastoma.
• Ivabridine - Inhibitor of If current in SA node... Approved for CHF and angina.
• Sacubitril - Inhibitor of neutral endopeptidase (neprilysin), combined with ARB for treatment of CHF.
• Alirocumab - Anti PCSK 9 Ab used to decrease LDL in familial hypercholesterolemia and CVS atherosclerotic disorders. PCSK 9 is a protein responsible for LDL receptors degradation in liver.
• Sonidegib - Hedgehog pathway inhibitor used for treatment of basal cell carcinoma recurrence after surgery and radiotherapy.
• Flibanserin - 5HT 1A agonist and 5HT 2C antagonist for hypoactive sexual desire disorder (HSDD).
• Paritaprevir - It is a Hep C virus protease inhibitor.
• Daclatasvir, Ombitasvir - NS5A protein inhibitors of hep C virus.
1. Daclatasvir is approved to be used with sofosbuvir for Hep C infection.
2. Ombitasvir is approved to be used with paritaprevir and ritonavir for Hep C virus infection.
• Brexpiprazole - Atypical antipsychtic approved for treatment of schizophrenia and depression
